Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch; Johannes S. De Jong; Jürgen Glatz; Panagiotis Symvoulidis; Laetitia E. Lamberts; Arthur L.L. Adams; Mariëtte E.G. Kranendonk; Anton G.T. Terwisscha Van Scheltinga; Michaela Aichler; Liesbeth Jansen; Jakob De Vries; Marjolijn N. Lub-De Hooge; Carolien P. Schröder; Annelies Jorritsma-Smit; Matthijs D. Linssen; Esther De Boer; Bert Van Der Vegt; Wouter B. Nagengast; Sjoerd G. Elias; Sabrina Oliveira; Arjen J. Witkamp; Willem P.Th M. Mali; Elsken Van Der Wall; P. Beatriz Garcia-Allende; Paul J. Van Diest; Elisabeth G.E. De Vries; Axel Walch; Gooitzen M. Van Dam; Vasilis Ntziachristos

doi:10.1117/12.2286062

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Maximilian Koch
, Johannes S. De Jong
, Jürgen Glatz
, Panagiotis Symvoulidis
, Laetitia E. Lamberts
, Arthur L.L. Adams
, Mariëtte E.G. Kranendonk
, Anton G.T. Terwisscha Van Scheltinga
, Michaela Aichler
, Liesbeth Jansen
, Jakob De Vries
, Marjolijn N. Lub-De Hooge
, Carolien P. Schröder
, Annelies Jorritsma-Smit
, Matthijs D. Linssen
, Esther De Boer
, Bert Van Der Vegt
, Wouter B. Nagengast
, Sjoerd G. Elias
, Sabrina Oliveira

Arjen J. Witkamp, Willem P.Th M. Mali, Elsken Van Der Wall, P. Beatriz Garcia-Allende, Paul J. Van Diest, Elisabeth G.E. De Vries, Axel Walch, Gooitzen M. Van Dam, Vasilis Ntziachristos

Lehrstuhl für Biologische Bildgebung

Publikation: Beitrag in Buch/Bericht/Konferenzband › Konferenzbeitrag › Begutachtung

Abstract

In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

Originalsprache	Englisch
Titel	Clinical and Preclinical Optical Diagnostics
Redakteure/-innen	J. Quincy Brown, Ton G. van Leeuwen
Herausgeber (Verlag)	SPIE
ISBN (elektronisch)	9781510612808
DOIs	https://doi.org/10.1117/12.2286062
Publikationsstatus	Veröffentlicht - 2017
Veranstaltung	Clinical and Preclinical Optical Diagnostics 2017 - Munich, Deutschland Dauer: 25 Juni 2017 → 27 Juni 2017

Publikationsreihe

Name	Progress in Biomedical Optics and Imaging - Proceedings of SPIE
Band	10411
ISSN (Print)	1605-7422

Konferenz

Konferenz	Clinical and Preclinical Optical Diagnostics 2017
Land/Gebiet	Deutschland
Ort	Munich
Zeitraum	25/06/17 → 27/06/17

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1117/12.2286062

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Koch, M., De Jong, J. S., Glatz, J., Symvoulidis, P., Lamberts, L. E., Adams, A. L. L., Kranendonk, M. E. G., Terwisscha Van Scheltinga, A. G. T., Aichler, M., Jansen, L., De Vries, J., Lub-De Hooge, M. N., Schröder, C. P., Jorritsma-Smit, A., Linssen, M. D., De Boer, E., Van Der Vegt, B., Nagengast, W. B., Elias, S. G., ... Ntziachristos, V. (2017). Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. in J. Q. Brown, & T. G. van Leeuwen (Hrsg.), Clinical and Preclinical Optical Diagnostics Artikel 104110F (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Band 10411). SPIE. https://doi.org/10.1117/12.2286062

@inproceedings{186fc58514a242199b572a81a60062ab,

title = "Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold",

abstract = "In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.",

author = "Maximilian Koch and \{De Jong\}, \{Johannes S.\} and J{\"u}rgen Glatz and Panagiotis Symvoulidis and Lamberts, \{Laetitia E.\} and Adams, \{Arthur L.L.\} and Kranendonk, \{Mari{\"e}tte E.G.\} and \{Terwisscha Van Scheltinga\}, \{Anton G.T.\} and Michaela Aichler and Liesbeth Jansen and \{De Vries\}, Jakob and \{Lub-De Hooge\}, \{Marjolijn N.\} and Schr{\"o}der, \{Carolien P.\} and Annelies Jorritsma-Smit and Linssen, \{Matthijs D.\} and \{De Boer\}, Esther and \{Van Der Vegt\}, Bert and Nagengast, \{Wouter B.\} and Elias, \{Sjoerd G.\} and Sabrina Oliveira and Witkamp, \{Arjen J.\} and Mali, \{Willem P.Th M.\} and \{Van Der Wall\}, Elsken and Garcia-Allende, \{P. Beatriz\} and \{Van Diest\}, \{Paul J.\} and \{De Vries\}, \{Elisabeth G.E.\} and Axel Walch and \{Van Dam\}, \{Gooitzen M.\} and Vasilis Ntziachristos",

note = "Publisher Copyright: {\textcopyright} COPYRIGHT SPIE. Downloading of the abstract is permitted for personal use only.; Clinical and Preclinical Optical Diagnostics 2017 ; Conference date: 25-06-2017 Through 27-06-2017",

year = "2017",

doi = "10.1117/12.2286062",

language = "English",

series = "Progress in Biomedical Optics and Imaging - Proceedings of SPIE",

publisher = "SPIE",

editor = "Brown, \{J. Quincy\} and \{van Leeuwen\}, \{Ton G.\}",

booktitle = "Clinical and Preclinical Optical Diagnostics",

}

Koch, M, De Jong, JS, Glatz, J, Symvoulidis, P, Lamberts, LE, Adams, ALL, Kranendonk, MEG, Terwisscha Van Scheltinga, AGT, Aichler, M, Jansen, L, De Vries, J, Lub-De Hooge, MN, Schröder, CP, Jorritsma-Smit, A, Linssen, MD, De Boer, E, Van Der Vegt, B, Nagengast, WB, Elias, SG, Oliveira, S, Witkamp, AJ, Mali, WPTM, Van Der Wall, E, Garcia-Allende, PB, Van Diest, PJ, De Vries, EGE, Walch, A, Van Dam, GM & Ntziachristos, V 2017, Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. in JQ Brown & TG van Leeuwen (Hrsg.), Clinical and Preclinical Optical Diagnostics., 104110F, Progress in Biomedical Optics and Imaging - Proceedings of SPIE, Bd. 10411, SPIE, Clinical and Preclinical Optical Diagnostics 2017, Munich, Deutschland, 25/06/17. https://doi.org/10.1117/12.2286062

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold. / Koch, Maximilian; De Jong, Johannes S.; Glatz, Jürgen et al.
Clinical and Preclinical Optical Diagnostics. Hrsg. / J. Quincy Brown; Ton G. van Leeuwen. SPIE, 2017. 104110F (Progress in Biomedical Optics and Imaging - Proceedings of SPIE; Band 10411).

Publikation: Beitrag in Buch/Bericht/Konferenzband › Konferenzbeitrag › Begutachtung

TY - GEN

T1 - Fluorescently labeled bevacizumab in human breast cancer

T2 - Clinical and Preclinical Optical Diagnostics 2017

AU - Koch, Maximilian

AU - De Jong, Johannes S.

AU - Glatz, Jürgen

AU - Symvoulidis, Panagiotis

AU - Lamberts, Laetitia E.

AU - Adams, Arthur L.L.

AU - Kranendonk, Mariëtte E.G.

AU - Terwisscha Van Scheltinga, Anton G.T.

AU - Aichler, Michaela

AU - Jansen, Liesbeth

AU - De Vries, Jakob

AU - Lub-De Hooge, Marjolijn N.

AU - Schröder, Carolien P.

AU - Jorritsma-Smit, Annelies

AU - Linssen, Matthijs D.

AU - De Boer, Esther

AU - Van Der Vegt, Bert

AU - Nagengast, Wouter B.

AU - Elias, Sjoerd G.

AU - Oliveira, Sabrina

AU - Witkamp, Arjen J.

AU - Mali, Willem P.Th M.

AU - Van Der Wall, Elsken

AU - Garcia-Allende, P. Beatriz

AU - Van Diest, Paul J.

AU - De Vries, Elisabeth G.E.

AU - Walch, Axel

AU - Van Dam, Gooitzen M.

AU - Ntziachristos, Vasilis

PY - 2017

Y1 - 2017

N2 - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

AB - In-vivo fluorescently labelled drug (bevacizumab) breast cancer specimen where obtained from patients. We propose a new structured method to determine the optimal classification threshold in targeted fluorescence intra-operative imaging.

UR - https://www.scopus.com/pages/publications/85033566002

U2 - 10.1117/12.2286062

DO - 10.1117/12.2286062

M3 - Conference contribution

AN - SCOPUS:85033566002

T3 - Progress in Biomedical Optics and Imaging - Proceedings of SPIE

BT - Clinical and Preclinical Optical Diagnostics

A2 - Brown, J. Quincy

A2 - van Leeuwen, Ton G.

PB - SPIE

Y2 - 25 June 2017 through 27 June 2017

ER -

Fluorescently labeled bevacizumab in human breast cancer: Defining the classification threshold

Abstract

Publikationsreihe

Konferenz

UN SDGs

Zugriff auf Dokument

Andere Dateien und Links

Fingerprint

Dieses zitieren